{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"133"},{"groupId":"OG002","value":"145"}],"units":"Participants"}],"description":"Participants with a best overall response of complete response, defined as negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and \\<5% plasma cells in bone marrow. Response was assessed by the Investigator using the IMWG uniform response criteria.","groups":[{"description":"Participants received bortezomib (Velcade) 1.3 mg/m\\^2 administered as a bolus intravenous (IV) injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).","id":"OG000","title":"Bortezomib and Dexamethasone"},{"description":"Participants received bortezomib 1.3 mg/m\\^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12, and thalidomide 100 mg orally on Days 1-21 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).","id":"OG001","title":"Bortezomib, Thalidomide, and Dexamethasone"},{"description":"Participants received bortezomib 1.3 mg/m\\^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and melphalan 9 mg/m\\^2 orally on Days 1-4 every other cycle and prednisone 60 mg/m\\^2 orally on Days 1-4 every other cycle for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).","id":"OG002","title":"Bortezomib, Melphalan and Prednisone"}],"paramType":"NUMBER","populationDescription":"Response-Evaluable population, defined as all participants who received at least 1 dose of any study drug, have measurable disease at baseline, and have at least one post-baseline M-protein measurement.","reportingStatus":"POSTED","timeFrame":"Response assessed every other cycle, for up to 13 cycles (49 weeks).","title":"Percentage of Participants With a Complete Response","type":"SECONDARY","unitOfMeasure":"percentage of participants"}